2024-09-27 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis Report

**Company Overview:** Abbott Laboratories is a global healthcare company that develops, manufactures, and markets a wide range of medical devices, pharmaceuticals, and nutritional products.

**Performance Analysis:**

**1. Rate of Return vs. S&P 500 (VOO):**

* **Cumulative Return:** 102.09%
* **S&P 500 (VOO) Cumulative Return:** 133.29%
* **Return Difference:** -31.2%
* **Relative Divergence:** 11.79% 

**Interpretation:** 
Over the period analyzed, Abbott Laboratories has underperformed the S&P 500 by approximately 31.2%. Its relative divergence score suggests that its performance has been in the lower 11.79% percentile of its historical range against the S&P 500.

**2. Recent Price Action:**

* **Closing Price:** $112.61
* **5-day Moving Average:** $113.66
* **20-day Moving Average:** $114.84
* **60-day Moving Average:** $109.61

**Interpretation:** 
The stock price is currently below both the 5-day and 20-day moving averages, indicating potential short-term downward pressure. However, it sits above the 60-day moving average, implying a longer-term upward trend.

**3. Technical Indicators:**

* **RSI:** 48.25
* **PPO:** -0.55
* **Delta_Previous_Relative_Divergence:** -3.89 (Short-term downward trend)
* **Expected_Return:** 0.0% (Maximum 5-year expected return based on current investment)

**Interpretation:**
The RSI indicates a neutral sentiment, neither oversold nor overbought. The PPO suggests a potential bearish momentum. The negative Delta_Previous_Relative_Divergence supports the short-term bearish trend. The expected return is currently negligible.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-07-31 | 0.74 | 10.38 B$ |
| 2024-05-02 | 0.7 | 9.96 B$ |
| 2023-11-01 | 0.82 | 10.14 B$ |
| 2023-08-03 | 0.79 | 9.98 B$ |
| 2024-07-31 | 0.79 | 9.98 B$ |

**Interpretation:**
The company has consistently reported a solid revenue stream. The most recent earnings for the quarter ending July 31st, 2024, showed a slight decrease in EPS compared to the previous quarter, but the revenue remained strong. 

**5. News and Recent Issues:**

* **Recent Market Outlook:** 
* **Analyst Opinions:**
* **Performance Highlights:**

To provide a comprehensive overview, I recommend researching recent news articles and reports from reputable sources like FINBOLD, Seeking Alpha, and Yahoo Finance. These resources will offer insights into current market sentiment, analyst opinions, and potential catalysts for the company's performance.

**6. Overall Analysis:**

Abbott Laboratories has a strong track record and a diversified business model. While it currently lags behind the S&P 500 in terms of returns, the recent earnings remain solid, and the stock's long-term trend remains positive. The recent short-term downward pressure should be monitored closely, but the company's long-term prospects remain promising.

**Recommendations:**

For a more informed investment decision, it's crucial to conduct further research and consider your individual investment goals and risk tolerance. Consult with a financial advisor before making any investment decisions.
